Skip to content

Zenas BioPharma, Inc.

ZBIO

CIK 0001953926

← back to feed
Revenue (TTM)
$10M
+100.0% YoY Q1 Apr 2026
Net Income (TTM)
−$218.28M
−140.6% YoY Q1 Apr 2026
EPS Diluted (TTM)
−$4.73
+29.0% YoY Q1 Apr 2026
Gross Margin
—
Q1 Apr 2026
Operating Margin
-2,224.2%
Q1 Apr 2026
Net Margin
-2,182.8%
Q1 Apr 2026
Free Cash Flow (TTM)
−$172.35M
Q1 Apr 2026
Cash
$500.22M
Q1 Apr 2026
Total Debt
$78.64M
Q1 Apr 2026
Shares Outstanding
63.13M sh
Q1 Apr 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings